Drug Search Results
More Filters [+]

A2B694

Alternative Names: A2B694
Latest Update: 2024-05-29
Latest Update Note: News Article

Product Description

A2B694 is a autologous CAR-T cell candidate from A2 Bio, which acts as a MSLN activator and HLA-A*02 blocker for the treatment of Ovarian, Mesothelioma, Colorectal, Lung and Pancreatic Cancers. (Sourced from: https://www.a2bio.com/our-pipeline/)

Mechanisms of Action: Cell Therapy,HLA

Novel Mechanism: Yes

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: A2 Bio
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for A2B694

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Adenocarcinoma|Colorectal Cancer|Mesothelioma|Non-Small-Cell Lung Cancer|Ovarian Cancer|Pancreatic Cancer|Squamous Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

EVEREST-2

P2

Recruiting

Ovarian Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer|Mesothelioma|Adenocarcinoma|Squamous Cell Carcinoma

2028-06-01

Recent News Events